PA · ALVAL.PA
Valbiotis S.A.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Périgny 17180
- Website
- valbiotis.com
Price · as of 2024-12-31
$0.93
Market cap 23.07M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $27.81 | +2,903.24% |
| Intrinsic Value(DCF) | $0.43 | -53.56% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $53.37 | +5,663.07% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | $0.00 | $0.00 | |||
| 2017 | $7.73 | $104.02 | $2.70 | $0.00 | $80.49 |
| 2018 | $4.12 | $288.26 | $0.48 | $0.00 | $0.00 |
| 2019 | $3.20 | $20.85 | $0.00 | $0.00 | $0.00 |
| 2020 | $7.84 | $658.47 | $71,644.87 | $0.00 | $0.00 |
| 2021 | $4.90 | $574.17 | $0.22 | $0.00 | $74.26 |
| 2022 | $4.16 | $40.42 | $0.01 | $0.00 | $0.00 |
| 2023 | $4.00 | $83.30 | $35,760.79 | $0.00 | $0.00 |
| 2024 | $1.08 | $27.81 | $0.00 | $0.00 | $53.37 |
AI valuation
Our deep-learning model estimates Valbiotis S.A.'s (ALVAL.PA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $27.81
- Current price
- $0.93
- AI upside
- +2,903.24%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.43
-53.56% upside
Graham-Dodd
—
— upside
Graham Formula
$53.37
+5,663.07% upside
About Valbiotis S.A.
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
- CEO
- Sebastien Peltier
- Employees
- 44
- Beta
- -0.19
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.43 ÷ $0.93) − 1 = -53.56% (DCF, example).